BG99074A - Рекомбинантни човешки нiv-неутрализиращи моноклонални антитела за профилактика и лечение на нiv инфекция - Google Patents

Рекомбинантни човешки нiv-неутрализиращи моноклонални антитела за профилактика и лечение на нiv инфекция

Info

Publication number
BG99074A
BG99074A BG99074A BG9907494A BG99074A BG 99074 A BG99074 A BG 99074A BG 99074 A BG99074 A BG 99074A BG 9907494 A BG9907494 A BG 9907494A BG 99074 A BG99074 A BG 99074A
Authority
BG
Bulgaria
Prior art keywords
treatment
recombinant human
prophylaxy
hiv
monoclonal antibodies
Prior art date
Application number
BG99074A
Other languages
English (en)
Inventor
Emilio Emini
Anthony Conley
George Mark
L. Johnson
David Pfarr
Original Assignee
Merck & Co. Inc.
Medimmune,Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc., Medimmune,Inc. filed Critical Merck & Co. Inc.
Publication of BG99074A publication Critical patent/BG99074A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретението се отнася до рекомбинантни човешки имуноглобулинови молекули, неутрализиращи нiv-1, до методи за получаване на имуноглобулини и методи за профилактика на нiv-1 инфекция чрез използване на имуноглобулини. Dnа (дезоксирибонуклеинова киселина) структурата съдържа допълнително определени области (сdrs) и структура (frs) от същинските човешки антитела, комбинирани с други постоянни области и експресирани рекомбинантни клетки гостоприемници. Посочените рекомбинантни антитела намират приложение за лечение и профилактика на нiv-1 инфекция in vivо.
BG99074A 1992-04-01 1994-09-28 Рекомбинантни човешки нiv-неутрализиращи моноклонални антитела за профилактика и лечение на нiv инфекция BG99074A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86170192A 1992-04-01 1992-04-01
PCT/US1993/002629 WO1993019785A1 (en) 1992-04-01 1993-03-23 Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection

Publications (1)

Publication Number Publication Date
BG99074A true BG99074A (bg) 1995-11-30

Family

ID=25336532

Family Applications (1)

Application Number Title Priority Date Filing Date
BG99074A BG99074A (bg) 1992-04-01 1994-09-28 Рекомбинантни човешки нiv-неутрализиращи моноклонални антитела за профилактика и лечение на нiv инфекция

Country Status (19)

Country Link
EP (1) EP0577243A3 (bg)
JP (1) JPH06217791A (bg)
KR (1) KR950700761A (bg)
CN (1) CN1081716A (bg)
AU (2) AU3928593A (bg)
BG (1) BG99074A (bg)
CA (1) CA2093099A1 (bg)
CZ (1) CZ239694A3 (bg)
FI (1) FI944561A (bg)
HU (1) HUT70461A (bg)
IL (1) IL105145A0 (bg)
MX (1) MX9301858A (bg)
NO (1) NO943653L (bg)
NZ (1) NZ251582A (bg)
RU (1) RU94045907A (bg)
SK (1) SK116294A3 (bg)
WO (1) WO1993019785A1 (bg)
YU (1) YU22693A (bg)
ZA (1) ZA932308B (bg)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE263778T1 (de) * 1998-10-30 2004-04-15 Novozymes As Niedrigallergene proteinvarianten
US7560529B2 (en) 2001-04-24 2009-07-14 FDS Pharma Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence
RU2221873C2 (ru) * 2001-04-24 2004-01-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
US8332159B2 (en) 2003-02-20 2012-12-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for enhancing efficacy of preparation of monoclonal antibody
WO2009029569A1 (en) * 2007-08-24 2009-03-05 Novartis Vaccines And Diagnostics Inc. Hiv env proteins with modifications in the v3 loop
PE20120106A1 (es) 2008-12-09 2012-02-20 Gilead Sciences Inc Moduladores de receptores tipo toll
US10421803B2 (en) 2014-01-31 2019-09-24 The Rockefeller University Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits
NZ728072A (en) 2014-07-11 2018-06-29 Gilead Sciences Inc Modulators of toll-like receptors for the treatment of hiv
CN110305133A (zh) 2014-09-16 2019-10-08 吉利德科学公司 Toll样受体调节剂的固体形式
WO2021227138A1 (zh) * 2020-05-09 2021-11-18 江苏省疾病预防控制中心(江苏省公共卫生研究院) 针对新型冠状病毒的单克隆抗体或其抗原结合部分

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366718B1 (en) * 1987-05-29 1995-05-10 Tanox Biosystems, Inc. Monoclonal antibodies neutralizing hiv-1
EP0311228A3 (en) * 1987-10-09 1990-05-02 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
IL94624A0 (en) * 1989-06-05 1991-04-15 Repligen Corp Human monoclonal antibodies to hiv-1 mn qq120
CA2087347C (en) * 1990-06-15 2004-03-30 Susan Zolla-Pazner Heterohybridomas producing human monoclonal antibodies to hiv-1
CA2128879A1 (en) * 1992-01-29 1993-08-05 Marie E. Beckner Aamp-1, a protein with local homologies to hiv-1 env and nef proteins

Also Published As

Publication number Publication date
NO943653D0 (no) 1994-09-30
SK116294A3 (en) 1996-11-06
YU22693A (sh) 1997-01-08
CZ239694A3 (en) 1995-07-12
EP0577243A2 (en) 1994-01-05
IL105145A0 (en) 1993-07-08
CA2093099A1 (en) 1993-10-02
CN1081716A (zh) 1994-02-09
JPH06217791A (ja) 1994-08-09
AU3563093A (en) 1993-10-07
KR950700761A (ko) 1995-02-20
AU658987B2 (en) 1995-05-04
AU3928593A (en) 1993-11-08
HUT70461A (en) 1995-10-30
WO1993019785A1 (en) 1993-10-14
EP0577243A3 (en) 1994-11-02
RU94045907A (ru) 1996-11-10
FI944561A0 (fi) 1994-09-30
NO943653L (no) 1994-11-30
HU9402824D0 (en) 1994-11-28
NZ251582A (en) 1997-07-27
MX9301858A (es) 1994-03-31
FI944561A (fi) 1994-09-30
ZA932308B (en) 1994-09-30

Similar Documents

Publication Publication Date Title
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
DK0626447T3 (da) Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen
AR045056A1 (es) Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
BG99074A (bg) Рекомбинантни човешки нiv-неутрализиращи моноклонални антитела за профилактика и лечение на нiv инфекция
ATE194291T1 (de) Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
DK442788D0 (da) Fremgangsmaade og praeparat til behandling af non-ige-medierede lidelser
EA200601715A1 (ru) Получение гуманизированных антител в [организме] трансгенных животных
NO982062L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav
ES2074042T3 (es) Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.
RU2000124084A (ru) Химерное антитело, которое связывается с CD40 человека (варианты), молекула нуклеиновой кислоты (варианты), вектор экспрессии (варианты), гуманизированное антитело (варианты), фармацевтическая композиция для лечения заболевания, опосредованного Т-клетками (варианты), способ лечения больного от заболевания, опосредованного Т-клетками (варианты)
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
RU2317998C2 (ru) Антитела человека, обладающие активностью связывания c mn и нейтрализации клеточной адгезии
BR9607171A (pt) Anticorpos monoclonais anti-cd6 e usos dos mesmos
OA07388A (fr) Nouveaux conjugués associant, par liaison convalente, une enzyme et un anticorps et associations médicamenteuses utilisant lesdits conjugués.
ES2194015T3 (es) Anticuerpos monoclonales humanos neutralizantes del virus de inmunodeficiencia humana.
DK0552296T3 (da) Monoklonale antistoffer fra mus
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
DE69824234D1 (de) Menschliche-"CDR-grafted"-Antikörper gegen Gangliosid gm2
FI934145A (fi) Omformade monoklonala antikroppar mot en immunoglobulinisotyp
DE69841331D1 (de) Humanisierte monoklonale antikörper die schützen gegen shigatoxininduzierte krankheiten
BG96346A (bg) Специфични свързващи вещества
SG128482A1 (en) Method and composition for altering a b cell mediated pathology
KR870700023A (ko) 녹농균의 E8Ag항원 및 그것에 대한 모노클로날 항체및 하이브리도마
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
RU2217166C2 (ru) Гуманизированные антитела, которые распознают веротоксин ii, и продуцирующая их линия клеток